01 Growth in Research and Development With the increasing prevalence of posterior segment eye disorders worldwide and the resulting demand for practical diagnostic and therapeutic approaches, companies in the field and other research institutions are continuously working to advance therapeutic options for posterior segment eye disorders through cutting-edge research and significant financial investment. As a result, this is anticipated to fuel the market's growth during the forecast period, as new therapeutics are predicted to increase procedure safety and lower costs. According to the Glaucoma Research Foundation's February 2020 report, selective laser trabeculoplasty (SLT), along with several other treatment options like micro-invasive glaucoma surgery, has become more prevalent in recent years due to technological advancements. Additionally, according to the same source, the number of drugs used to treat glaucoma that have received regulatory authority approval in recent years has increased, which is expected to fuel growth in the market under further study.
02 Conscious Regulatory Actions The posterior segment eye disorders market is regulated by regulatory bodies established by various governments of the world through strict regulatory policies to ensure public access to safe, appropriate, and affordable diagnostic and therapeutic products. This impacts manufacturers by delaying approvals and pr. Strict regulations make it harder for pharmaceutical companies to comply with outdated or incompatible laws and the process for a new commercial test to gain regulatory marketing approval. Depending on the drug's complexity, this process may be expensive and time-consuming. Many therapeutic ideas never reach a clinical trial, where efficacy and safety are assessed on volunteer patients. Sometimes, a promising drug or therapy is never released to the market due to compliance or safety issues, which also affects market development. The strict regulations around the world impact manufacturers in terms of product approvals and other ways, which is expected to slow the growth of the posterior segment eye disorders market globally during the forecast period.
01 Lack of Primary Infrastructure in Underdeveloped and Developing Countries In developing and underdeveloped nations, the population and the disease burden are expanding quickly. This strain on the medical and healthcare systems is caused by the absence of adequate healthcare infrastructure for conditions like eye diseases and other conditions related to the eyes in these areas. Therefore, it is anticipated that fewer disorders associated with the posterior segment of the eye will be identified or treated due to the lack of medical resources in these areas, which may impede the growth of the studied market over the forecast period. Additionally, because there is a need for primary healthcare infrastructure in these developing and underdeveloped countries, diagnostic and treatment services are very expensive and primarily provided by private healthcare providers, which impacts the region's poor. As a result, the accessibility of healthcare services declines in developing and underdeveloped regions, which has a detrimental effect on the market's expansion.
01 Rising Incidence of Diseases to Aid Market Growth Future market growth for posterior segment eye disorders will be primarily driven by the rising incidence of diseases affecting the posterior segment of the eye, their risk factors, including diabetes and aging, and the introduction of new therapeutic products. Additionally, it is anticipated that the burden of posterior segment eye disorders will rise due to the rising prevalence of risk factors like diabetes worldwide, which will fuel the study market's expansion over the coming years. Furthermore, the expansion of research and development in the field and new funding for the creation of potent therapeutics to treat conditions affecting the posterior segment of the eye will result in the introduction of powerful new drugs and a greater understanding of these conditions, both of which will contribute to the future expansion of the market under study.
June 2026 Roche announced positive Phase III clinical results supporting the expansion of Vabysmo® for additional retinal disease indications, strengthening its ophthalmology portfolio.
May 2026 Bayer expanded the global commercialization of Eylea™ 8 mg following additional regulatory approvals for retinal disease treatment in international markets.
March 2026 Regeneron Pharmaceuticals received additional regulatory approvals for Eylea HD® in new markets, expanding treatment options for patients with retinal vascular disorders.
October 2025 Apellis Pharmaceuticals expanded the availability of Syfovre® through additional international regulatory and commercial initiatives for geographic atrophy treatment.
July 2025 AbbVie advanced the clinical development of next-generation ophthalmology therapies targeting retinal and posterior segment eye disorders through expanded global clinical programs.